Monday, September 14, 2026

North Korea, Early Next Year “Kim Jong-un-ism” Strengthening Observation… Labor Party Regulation Modification Attention

North Korea's upcoming 9th Party Congress may formalize Kim Jong Un's people-first ideology and state-first principles in party governance.

North Korea Is Tearing Down South Korean Resorts—But What Comes Next?

North Korea is dismantling South Korean facilities at Mount Kumgang, but redevelopment plans remain unclear despite potential UNESCO listing.

Did Tesla Stocks Soar Because of Cathie Wood?

Cathie Wood, the head of Ark Invest,...

Tag: Biotech

North KoreaKoreaKimMilitaryAISouth Koreamarketrelationsdevelopment

Yuhan’s Leclaza Wins Best Pharmaceutical Product at Asia’s First Prix Galien Awards

Yuhan Corporation's lung cancer drug 'Lecanza' wins Best Pharmaceutical Product at the inaugural 'Prix Galien' in Asia.

Top 5 Promising Lung Cancer Treatments Revealed at WCLC 2026: What You Need to Know

The world's largest conference on lung cancer will be held in Seoul after 19 years, showcasing clinical results from local pharmaceutical firms.

HLB Panagene Introduces PNA Technology at U.S. Conference, Seeks Global Partnerships

HLB Panagene introduced its peptide nucleic acid technology at a U.S. conference and discussed research and business collaboration opportunities with global pharmaceutical and biotech companies.

Alteogen Signs Subcutaneous Injection Development Deal With Novartis Worth Up to $3.22 Billion

Alteogen has signed an option and licensing agreement with Novartis to develop and commercialize subcutaneous formulations based on its ALT-B4 technology, with potential payments of up to $3.22 billion plus royalties.

SK Biopharmaceuticals Secures 795 Million USD License for Groundbreaking Epilepsy Drug Opacalim – What You Need to Know

SK Biopharmaceuticals acquires epilepsy drug candidate from Biohaven for 795 million USD, enhancing its global biotech portfolio.

Unlocking Biosimilar Success: Key Insights from the WHO Workshop in Asia

The Korean Ministry of Food and Drug Safety collaborates with WHO to unify biosimilar review standards in the Asia-Pacific region.

How the New BINSA Law Will Transform K-Bio: Opportunities and Challenges for Korean Companies

U.S. Congress is pushing for investment regulations targeting China's biotech industry, impacting global supply chains and local firms.

FDA Adjusts Drug Review Fees: Higher for New Drugs, Lower for Generics

The FDA’s 2027 fee changes lower review costs for new drugs and biosimilars while raising fees for generics and medical devices, with the impact varying by company.

Yuhan Corp., Celltrion and LigaChem Bio…K-Pharma Firms Move to Boost Corporate Value

The pharmaceutical and biotech sectors are boosting shareholder trust and corporate value through stock buybacks and retirements.

Kolon Group’s Biotech Bet Faces Uncertainty as October Trial Readout Becomes Critical

Kolon TissueGene's TG-C osteoarthritis treatment failed its first U.S. Phase 3 trial, raising doubts about the biotech's future.

Celltrion Group’s 2 Trillion KRW Investment: What It Means for Global Bio Manufacturing by 2032

Celltrion Group plans a 2 trillion KRW investment to enhance production capacity and establish a leading position in global biotech.

Regenerative Medicine Expanded to Four Diseases Including Knee Osteoarthritis; Medipost and CHA Biotech Seen as Potential Beneficiaries

The Korean government is easing regulations on regenerative medicine, boosting biotech, and enabling patient access to validated therapies.

Hanmi Pharmaceutical completes acquisition of Aptose Biosciences

Hanmi Pharmaceutical has acquired Aptose Biosciences for $46.7 million, regaining rights to the cancer drug tuspetinib.

Galux: “Beyond Molecular Design, AI Will Run Entire Drug Discovery Process Within 10 Years”

Generative AI in drug discovery is evolving towards agentic AI, which will autonomously manage the entire process, says Galux CEO Seok Chaok.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.